Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

被引：48
|
作者：
Stader, Felix [1 ,2 ,3 ]
Khoo, Saye [4 ]
Stoeckle, Marcel [1 ,2 ,3 ]
Back, David [4 ]
Hirsch, Hans H. [1 ,2 ,5 ]
Battegay, Manuel [1 ,2 ,3 ]
Marzolini, Catia [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland
[2] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[5] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 10期
关键词：
ENZYMES; CYP1A2; CYP3A4;
D O I：
10.1093/jac/dkaa253
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
下载
收藏
页码：3084 / 3086
页数：3
相关论文
共 50 条
  • [41] An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
    Ader, Florence
    Peiffer-Smadja, Nathan
    Poissy, Julien
    Bouscambert-Duchamp, Maude
    Belhadi, Drifa
    Diallo, Alpha
    Delmas, Christelle
    Saillard, Juliette
    Dechanet, Aline
    Mercier, Noemie
    Dupont, Axelle
    Alfaiate, Toni
    Lescure, Francois-Xavier
    Raffi, Francois
    Goehringer, Francois
    Kimmoun, Antoine
    Jaureguiberry, Stephane
    Reignier, Jean
    Nseir, Saad
    Danion, Francois
    Clere-Jehl, Raphael
    Bouiller, Evin
    Navellou, Jean-Christophe
    Tolsma, Violaine
    Cabie, Andre
    Dubost, Clement
    Courjon, Johan
    Leroy, Sylvie
    Mootien, Joy
    Gaci, Rostane
    Mourvillier, Bruno
    Faure, Emmanuel
    Pourcher, Valerie
    Gallien, Sebastien
    Launay, Odile
    Lacombe, Karine
    Lanoix, Jean-Philippe
    Makinson, Alain
    Martin-Blondel, Guillaume
    Bouadma, Lila
    Botelho-Nevers, Elisabeth
    Gagneux-Brunon, Amandine
    Epaulard, Olivier
    Piroth, Lionel
    Wallet, Florent
    Richard, Jean-Christophe
    Reuter, Jean
    Staub, Therese
    Lina, Bruno
    Noret, Marion
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (12) : 1826 - 1837
  • [42] Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review
    Vargas, M.
    Servillo, G.
    Einav, S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (16) : 8592 - 8605
  • [43] Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
    Amani, Bahma
    Khanijhani, Ahmad
    Amani, Behnam
    Hashemi, Payam
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2021, 24 : 246 - 257
  • [44] Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
    Chong, Vui Heng
    Chong, Pui Lin
    Metussin, Dhiya
    Asli, Rosmonaliza
    Momin, Riamiza Natalie
    Mani, Babu Ivan
    Abdullah, Muhammad Syafiq
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2322 - 2324
  • [45] A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
    Joumaa, H.
    Regard, L.
    Carlier, N.
    Chassagnon, G.
    Alabadan, E.
    Canoui, E.
    L'honneur, A.
    Rozenberg, F.
    Burgel, P. -R.
    Roche, N.
    RESPIRATORY MEDICINE AND RESEARCH, 2020, 78
  • [46] IN-SILICO MODELLING STUDIES ON RITONAVIR AND LOPINAVIR TO COMBAT COVID-19
    Tuteja, Jasdev Singh
    Chitnis, Kshitij
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (10): : 5247 - 5253
  • [47] A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
    Cao, B.
    Wang, Y.
    Wen, D.
    Liu, W.
    Wang, Jingli
    Fan, G.
    Ruan, L.
    Song, B.
    Cai, Y.
    Wei, M.
    Li, X.
    Xia, J.
    Chen, N.
    Xiang, J.
    Yu, T.
    Bai, T.
    Xie, X.
    Zhang, L.
    Li, C.
    Yuan, Y.
    Chen, H.
    Li, Huadong
    Huang, H.
    Tu, S.
    Gong, F.
    Liu, Y.
    Wei, Y.
    Dong, C.
    Zhou, F.
    Gu, X.
    Xu, J.
    Liu, Z.
    Zhang, Y.
    Li, Hui
    Shang, L.
    Wang, K.
    Li, K.
    Zhou, X.
    Dong, X.
    Qu, Z.
    Lu, S.
    Hu, X.
    Ruan, S.
    Luo, S.
    Wu, J.
    Peng, L.
    Cheng, F.
    Pan, L.
    Zou, J.
    Jia, C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1787 - 1799
  • [48] Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
    Joseph, Betsy Ann
    Dibas, Mahmoud
    Evanson, Kirk W.
    Paranjape, Geeta
    Vegivinti, Charan Thej Reddy
    Selvan, Pragadeesh Thamarai
    Saravu, Kavitha
    Gupta, Nitin
    Pulakurthi, Yashwitha Sai
    Keesari, Praneeth Reddy
    Varsha, Sriram
    Chittajallu, Spandana
    Dmytriw, Adam A.
    Reierson, Natalie L.
    Mikoff, Nick
    Kamrowski, Shelby
    Schmidt, Megan
    Davis, Amber R.
    Pederson, John M.
    Mishra, Hemant K.
    Touchette, Jillienne C.
    Kallmes, Kevin
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (06) : 679 - 687
  • [49] Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19
    Qu, Jian
    Li, Guo-Hua
    Wang, Jiao-Jiao
    He, Ge-Fei
    Huang, Juan-Juan
    Chen, Ying
    Qu, Qiang
    Chen, Xiang-Yu
    Lu, Qiong
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2021, 48 (02) : 203 - 210
  • [50] Lopinavir pharmacokinetics in COVID-19 patients
    Gregoire, Matthieu
    Le Turnier, Paul
    Gaborit, Benjamin J.
    Veyrac, Gwenaelle
    Lecomte, Raphael
    Boutoille, David
    Canet, Emmanuel
    Imbert, Berthe-Marie
    Bellouard, Ronan
    Raffi, Francois
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2702 - 2704
12345